// App-Quantinova.ai

746 : AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR+) solid tumors: Initial results from the phase 1 dose-escalation study

Researchers

Presenter

  • Omar Saavedra Santa Gadea

Principal Investigators

  • Daniela Morales-Espinosa

  • Juanita Lopez

  • Eric Christenson

  • Anthony El-Khoueiry

  • Andres Cervantes

  • Christa Raab

  • Ulrike Gärtner

  • Kerstin Pietzko

  • Laura Kohlhas

  • Daniel Schütz

  • Gabriele Hintzen

  • Paulien Ravenstijn

  • Michael Emig

  • Pilar Nava-Parada

Medical Centers

  • Hospital Clinico Universitario, Valencia, Valencia, Spain

  • University of Southern California, Los Angeles, CA

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Royal Marsden Hospital, London,

  • john hopkins university hospital, Baltimore, MD

  • Affimed, Heidelberg, Germany

Locations

  • Spain

  • United States

  • Germany

  • United Kingdom

Companies

  • Affimed GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Expansion Study

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT05109442

Sponsors

  • Affimed

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved